GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms
GSK's Arexvy maintains its RSV market dominance, looks to key label expansion as Moderna's mRNA threat looms
zbecker
СМИ24.net — правдивые новости, непрерывно 24/7 на русском языке с ежеминутным обновлением *
